...
search icon
ibrx-img

Immunitybio Inc, Common Stock

IBRX

NSQ

$3.42

-$0.22

(-6.04%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.50B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
5.15M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.19
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.28 L
$10.53 H
$3.42

About Immunitybio Inc, Common Stock

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameIBRXSectorS&P500
1-Week Return-5.52%1.67%0.11%
1-Month Return6.21%3.31%1.23%
3-Month Return-32.08%2.21%2.87%
6-Month Return-22.27%-4.82%8.93%
1-Year Return-26.92%1.22%22.83%
3-Year Return-51.69%15.75%42.13%
5-Year Return-40.52%42.34%83.14%
10-Year Return-90.13%103.03%189.73%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue2.20M605.00K934.00K240.00K622.00K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":27.48,"profit":true},{"date":"2021-12-31","value":42.42,"profit":true},{"date":"2022-12-31","value":10.9,"profit":true},{"date":"2023-12-31","value":28.25,"profit":true}]
Cost of Revenue9.01M9.15M-24.19M18.51M[{"date":"2019-12-31","value":37.25,"profit":true},{"date":"2020-12-31","value":37.81,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":76.52,"profit":true}]
Gross Profit(6.81M)(8.54M)934.00K(23.95M)622.00K[{"date":"2019-12-31","value":-729.12,"profit":false},{"date":"2020-12-31","value":-914.56,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-2564.45,"profit":false},{"date":"2023-12-31","value":66.6,"profit":true}]
Gross Margin(309.26%)(1411.90%)100.00%(9980.00%)100.00%[{"date":"2019-12-31","value":-309.26,"profit":false},{"date":"2020-12-31","value":-1411.9,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-9980,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses158.45M210.82M331.21M350.86M362.87M[{"date":"2019-12-31","value":43.67,"profit":true},{"date":"2020-12-31","value":58.1,"profit":true},{"date":"2021-12-31","value":91.28,"profit":true},{"date":"2022-12-31","value":96.69,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(156.25M)(220.88M)(330.28M)(351.30M)(362.25M)[{"date":"2019-12-31","value":-15625100000,"profit":false},{"date":"2020-12-31","value":-22088000000,"profit":false},{"date":"2021-12-31","value":-33028000000,"profit":false},{"date":"2022-12-31","value":-35129800000,"profit":false},{"date":"2023-12-31","value":-36225000000,"profit":false}]
Total Non-Operating Income/Expense(7.17M)(32.71M)(33.57M)(126.80M)(345.27M)[{"date":"2019-12-31","value":-716800000,"profit":false},{"date":"2020-12-31","value":-3270900000,"profit":false},{"date":"2021-12-31","value":-3357200000,"profit":false},{"date":"2022-12-31","value":-12679500000,"profit":false},{"date":"2023-12-31","value":-34527500000,"profit":false}]
Pre-Tax Income(160.26M)(226.03M)(349.84M)(417.29M)(583.89M)[{"date":"2019-12-31","value":-16026300000,"profit":false},{"date":"2020-12-31","value":-22603300000,"profit":false},{"date":"2021-12-31","value":-34983900000,"profit":false},{"date":"2022-12-31","value":-41728600000,"profit":false},{"date":"2023-12-31","value":-58389200000,"profit":false}]
Income Taxes(105.00K)(1.85M)9.00K34.00K(40.00K)[{"date":"2019-12-31","value":-308.82,"profit":false},{"date":"2020-12-31","value":-5429.41,"profit":false},{"date":"2021-12-31","value":26.47,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-117.65,"profit":false}]
Income After Taxes(160.16M)(224.19M)(349.85M)(417.32M)(583.85M)[{"date":"2019-12-31","value":-16015800000,"profit":false},{"date":"2020-12-31","value":-22418700000,"profit":false},{"date":"2021-12-31","value":-34984800000,"profit":false},{"date":"2022-12-31","value":-41732000000,"profit":false},{"date":"2023-12-31","value":-58385200000,"profit":false}]
Income From Continuous Operations(160.16M)(92.38M)(349.85M)(417.32M)(458.76M)[{"date":"2019-12-31","value":-16015800000,"profit":false},{"date":"2020-12-31","value":-9238300000,"profit":false},{"date":"2021-12-31","value":-34984800000,"profit":false},{"date":"2022-12-31","value":-41732000000,"profit":false},{"date":"2023-12-31","value":-45876400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(160.16M)(224.19M)(349.85M)(417.32M)(583.20M)[{"date":"2019-12-31","value":-16015800000,"profit":false},{"date":"2020-12-31","value":-22418700000,"profit":false},{"date":"2021-12-31","value":-34984800000,"profit":false},{"date":"2022-12-31","value":-41732000000,"profit":false},{"date":"2023-12-31","value":-58319600000,"profit":false}]
EPS (Diluted)(0.71)(0.89)(0.89)(1.05)(1.13)[{"date":"2019-12-31","value":-71,"profit":false},{"date":"2020-12-31","value":-89,"profit":false},{"date":"2021-12-31","value":-89,"profit":false},{"date":"2022-12-31","value":-105,"profit":false},{"date":"2023-12-31","value":-113,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IBRX
Cash Ratio 2.14
Current Ratio 2.68
Quick Ratio 2.64

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IBRX
ROA (LTM) -56.35%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IBRX
Debt Ratio Lower is generally better. Negative is bad. 3.04
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -2.04

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IBRX
Trailing PE NM
Forward PE NM
P/S (TTM) 362.49
P/B 0.00
Price/FCF NM
EV/R 471.93
EV/Ebitda NM

FAQs

What is Immunitybio Inc share price today?

Immunitybio Inc (IBRX) share price today is $3.42

Can Indians buy Immunitybio Inc shares?

Yes, Indians can buy shares of Immunitybio Inc (IBRX) on Vested. To buy Immunitybio Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IBRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Immunitybio Inc be purchased?

Yes, you can purchase fractional shares of Immunitybio Inc (IBRX) via the Vested app. You can start investing in Immunitybio Inc (IBRX) with a minimum investment of $1.

How to invest in Immunitybio Inc shares from India?

You can invest in shares of Immunitybio Inc (IBRX) via Vested in three simple steps:

  • Click on Sign Up or Invest in IBRX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Immunitybio Inc shares
What is Immunitybio Inc 52-week high and low stock price?

The 52-week high price of Immunitybio Inc (IBRX) is $10.53. The 52-week low price of Immunitybio Inc (IBRX) is $2.28.

What is Immunitybio Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Immunitybio Inc (IBRX) is 0.00

What is the Market Cap of Immunitybio Inc?

The market capitalization of Immunitybio Inc (IBRX) is $2.50B

What is Immunitybio Inc’s stock symbol?

The stock symbol (or ticker) of Immunitybio Inc is IBRX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top